文献速递糖尿病

跨时区旅行中1型糖尿病:德谷胰岛素与甘精胰岛素U100对比初步研究

Traveling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100.
PubMed 文献 · Diabetes Care · 2022-01-01

该随机交叉初步研究比较了每日多次注射胰岛素的1型糖尿病成人患者跨多时区旅行时,德谷胰岛素与甘精胰岛素U100作为基础胰岛素的血糖控制情况。主要终点为每个方向旅行后初始24小时内70-140 mg/dL的TIR百分比,两组血糖结局无显著差异,且均未达到70% TIR 70-180 mg/dL。东行时甘精U100的时差反应更大,西行后甘精组疲劳更明显,睡眠无显著差异。

要点

  • 德谷胰岛素与甘精U100在跨时区旅行中血糖结局相似。
  • 两组均未达到70% TIR 70-180 mg/dL。
  • 东行时甘精U100时差反应更大,西行后疲劳更明显。

核心结论

  • 在跨多时区旅行的1型糖尿病成人MDI患者中,德谷胰岛素与甘精胰岛素U100的血糖结局相似。

研究设计与样本

  • 随机交叉初步研究,纳入25例使用MDI的1型糖尿病成人,比较德谷胰岛素与甘精胰岛素U100在往返夏威夷与纽约长途旅行中的效果。

主要发现

  • 两组在TIR、低血糖或高血糖方面无显著差异。
  • 旅行期间两组均未达到>70% TIR 70-180 mg/dL。
  • 东行时甘精U100的时差反应更大,西行后甘精组疲劳更明显。
  • 睡眠在两种基础胰岛素间无显著差异。

关键数值与推荐

  • 主要终点为每个方向旅行后初始24小时内70-140 mg/dL的TIR百分比。
  • 德谷胰岛素每日固定时间给药,甘精胰岛素按旅行算法给药。

临床怎么用

  • 跨时区旅行时德谷胰岛素可每日固定时间给药,甘精胰岛素需按旅行算法调整。
  • 两种基础胰岛素在旅行期间血糖控制相似,但需注意时差反应和疲劳的差异。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: For people with type 1 diabetes, there are limited evidence-based resources to support self-management when traveling across multiple time zones. Here, we compared glycemic control on insulin degludec versus glargine U100 as the basal insulin for adults using multiple daily injections (MDI) while traveling across multiple time zones. RESEARCH DESIGN AND METHODS: This randomized crossover pilot study compared insulin degludec versus glargine U100 for adults with type 1 diabetes using MDI insulin during long-haul travel to and from Hawaii to New York. Insulin degludec was administered daily at the same time regardless of time zone, and glargine was administered per travel algorithm. Primary end point was the percentage of time in range (TIR) between 70 and 140 mg/dL during the initial 24 h after each direction of travel. Secondary end points included standard continuous glucose monitoring metrics, jet lag, fatigue, and sleep. RESULTS: The study enrolled 25 participants (56% women, mean ± SD age of 35 ± 14.5 years, HbA1c of 7.4 ± 1.2% [57 ± 13.1 mmol/mol], and diabetes duration of 20.6 ± 15 years). There was no significant difference in glycemic outcomes between the two arms of the study, including TIR, hypoglycemia, or hyperglycemia. Neither group achieved >70% TIR 70-180 mg/dL during travel. Jet lag was greater on glargine U100 in eastward travel but not westward. Fatigue was greater after westward travel on glargine. Sleep was not significantly different between basal insulins. CONCLUSIONS: In adults with type 1 diabetes using MDI of insulin and traveling across multiple time zones, glycemic outcomes were similar comparing insulin degludec and glargine U100.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bevier WC, Castorino KN, Axelrod C, et al. Traveling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100. Diabetes Care. 2022. PMID: 34716211. doi:10.2337/dc21-1524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。